Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer and UCB. The departures coincided with ...

GSK) and Pfizer’s consumer healthcare businesses. Subsequently, in July 2022, GSK spun off Haleon as an independent publicly traded company. Haleon owns popular brands such as Sensodyne ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

Is it true that the higher the dividend yield, the riskier the dividend? Not always. Some companies with exceptionally high ...

Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist ...

Editorial Note: Blueprint may earn a commission from affiliate partner links featured here on our site. This commission does not influence our editors' opinions or evaluations. Please view our ...

Are you a print subscriber? Activate your account. By Tim Nudd - 1 hour 14 min ago By Adrianne Pasquarelli - 5 hours 42 min ago By Erika Wheless - 5 hours 42 min ago By Brian Bonilla - 5 hours 42 ...

At the time, Pfizer was pivoting away from its consumer healthcare business with a GSK (GSK) joint venture and had spun off its generics business Upjohn. The company was just starting to contend with ...

During the same period, the company received roughly $6.9 billion of net cash proceeds from the sale of its shares of Haleon, a consumer health joint venture with GSK. In Pfizer's Q3 earnings call ...